Cullinan Therapeutics (CGEM) Accumulated Expenses: 2020-2023
Historic Accumulated Expenses for Cullinan Therapeutics (CGEM) over the last 3 years, with Sep 2023 value amounting to $20.9 million.
- Cullinan Therapeutics' Accumulated Expenses rose 55.08% to $20.9 million in Q3 2023 from the same period last year, while for Sep 2023 it was $20.9 million, marking a year-over-year increase of 55.08%. This contributed to the annual value of $14.1 million for FY2022, which is 64.80% up from last year.
- Per Cullinan Therapeutics' latest filing, its Accumulated Expenses stood at $20.9 million for Q3 2023, which was up 34.87% from $15.5 million recorded in Q2 2023.
- Over the past 5 years, Cullinan Therapeutics' Accumulated Expenses peaked at $20.9 million during Q3 2023, and registered a low of $4.2 million during Q2 2021.
- Its 3-year average for Accumulated Expenses is $11.8 million, with a median of $11.9 million in 2022.
- Data for Cullinan Therapeutics' Accumulated Expenses shows a peak YoY skyrocketed of 181.15% (in 2022) over the last 5 years.
- Quarterly analysis of 4 years shows Cullinan Therapeutics' Accumulated Expenses stood at $4.6 million in 2020, then soared by 84.81% to $8.6 million in 2021, then skyrocketed by 64.80% to $14.1 million in 2022, then skyrocketed by 55.08% to $20.9 million in 2023.
- Its last three reported values are $20.9 million in Q3 2023, $15.5 million for Q2 2023, and $18.4 million during Q1 2023.